

# MYELOMA VIIIth trial

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>25/10/2000   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered    |
|  |   | <input type="checkbox"/> Protocol                    |
| <b>Registration date</b><br>25/10/2000 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan   |
|  |   | <input type="checkbox"/> Results                     |
| <b>Last Edited</b><br>27/09/2019       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data |
|  |   | <input type="checkbox"/> Record updated in last year |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Mark Drayson

**Contact details**  
Department of Immunology  
Medical School  
University of Birmingham  
Vincent Drive  
Birmingham  
United Kingdom  
B15 2TT  
-  
m.t.draysom@bham.ac.uk

## Additional identifiers

**Protocol serial number**  
G8003737 expired Oct 99

## Study information

**Scientific Title**  
MYELOMA VIIIth trial

**Acronym**

MYELOMA VIIIth trial

**Study objectives**

To compare, for survival, the induction of first plateau phase in previously untreated patients with multiple myeloma, the efficacy of the above two treatments

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration.

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Leukaemia

**Interventions**

All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Cyclophosphamide and ABCM

**Primary outcome(s)**

1. Survival
2. Obtaining plateau (stable disease with no more than minimal symptoms)
3. Quality of life

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/11/2000

**Eligibility**

**Key inclusion criteria**

1. Greater than 65 years old and less than 75 years old
2. Myeloma
3. No previous cytotoxic therapy
4. Neutrophil count greater than or equal to  $1.3 \times 10^9/l$
5. Platelet count greater than or equal to  $75 \times 10^9/L$
6. Able to tolerate 3 l of fluid per day
7. Apyrexial
8. Free from infection
9. Informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

Not Specified

**Key exclusion criteria**

Patients with equivocal myelomatosis

**Date of first enrolment**

01/11/1993

**Date of final enrolment**

01/11/2000

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Department of Immunology

Birmingham

United Kingdom

B15 2TT

**Sponsor information**

**Organisation**

Medical Research Council (MRC) (UK)

**Funder(s)****Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration